Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction. An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar. continue reading below »
REACH is a free program* that supports your patients and encourages active participation in their therapy. Through the Resources for Expert Assistance and Care Helpline (1.866.NEXAVAR [1.866.639.2827]), REACH counselors are available to provide:
Assistance with medication access and compliance
Reimbursement and financial support for the best coverage possible
Education and guidance when your patients need it most
*Participation in the REACH program is not contingent on future Nexavar purchases.
†This program is not for patients receiving prescription reimbursement under any federal- , state- , or government-funded insurance programs or where prohibited by law. Patients are responsible for reporting co-pay assistance to their insurance company.
‡This program is not for patients receiving prescription reimbursement under any federal- , state- , or government-funded insurance programs or for patients who live in Massachusetts or where prohibited by law.
§Translation services are available for non-English-speaking patients in many languages via phone interpreters.